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Background: Bioinformatic analysis revealed that PAR4 possesses an ER retention motif.
Results: PAR2 both abrogates and facilitates chaperone protein interaction with PAR4 to allow PAR4 to evade ER retention and
be delivered to the plasma membrane.
Conclusion: PAR2 regulates PAR4 localization and cell signaling through heterodimerization.
Significance: Impact upon understanding PAR2 and PAR4 in inflammation where clear roles are defined.
Proteinase-activated receptors 4 (PAR4) is a classAGprotein-
coupled receptor (GPCR) recognized through the ability of ser-
ine proteases such as thrombin and trypsin to mediate receptor
activation. Due to the irreversible nature of activation, a fresh
supply of receptor is required to bemobilized to the cell surface
for responsiveness to agonist to be sustained. Unlike other PAR
subtypes, the mechanisms regulating receptor trafficking of
PAR4 remain unknown. Here, we report novel features of the
intracellular trafficking of PAR4 to the plasmamembrane. PAR4
was poorly expressed at the plasma membrane and largely
retained in the endoplasmic reticulum (ER) in a complex with
theCOPIprotein subunit-COP1.Analysis of thePAR4protein
sequence identified an arginine-based (RXR) ER retention
sequence located within intracellular loop-2 (R183AR 3
A183AA), mutation of which allowed efficient membrane deliv-
ery of PAR4. Interestingly, co-expression with PAR2 facilitated
plasmamembrane delivery of PAR4, an effect produced through
disruption of -COP1 binding and facilitation of interaction
with the chaperone protein 14-3-3. Intermolecular FRET stud-
ies confirmed heterodimerization between PAR2 and PAR4.
PAR2 also enhanced glycosylation of PAR4 and activation of
PAR4 signaling. Our results identify a novel regulatory role
for PAR2 in the anterograde traffic of PAR4. PAR2 was shown to
both facilitate and abrogate protein interactions with PAR4,
impacting upon receptor localization and cell signal transduc-
tion. This work is likely to impact markedly upon the under-
standing of the receptor pharmacology of PAR4 in normal phys-
iology and disease.
Proteinase-activated receptors (PARs)2 are a class A GPCR
family comprised of four family members, PAR1 through to
PAR4, which play key roles in aspects of both physiology and
pathophysiology including platelet aggregation, wound heal-
ing, and various aspects of inflammation (1–3). Detailed char-
acterization of the protein structure of the PAR family has iden-
tified proteolytic cleavage sites at the receptor N-terminal
(4–7). For each receptor a unique tethered ligand is exposed
within the N-terminal that interacts with the second extracel-
lular loop to mediate receptor activation. The structural deter-
minants that regulate PAR activation have long been of interest
and there has been considerable focus placed upon the mecha-
nisms underpinning membrane trafficking and signal termina-
tion particularly for PAR1 (8–14) and PAR2 (15–19). The most
recent family member to be cloned, PAR4 (20, 21), is distinct
from both PAR1 and PAR2. Although a thrombin-activated
receptor, it lacks the hirudin-like domain required for throm-
bin selectivity and is activated by several other ligands including
trypsin. In addition it has a shorter C terminus than PAR1 and
PAR2 and lacks essential phosphorylation sites within intracel-
lular domains, which are present in other family members and
have been shown to be necessary for receptor desensitization
(22). PAR4 has been poorly studied relative to either PAR1 or
PAR2 but has been shown to signal viaCa2mobilization and to
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regulate theMAP kinases (23). However, very little is known of
the mechanisms regulating receptor trafficking.
Due to the irreversible nature of activation of PARs, for
responsiveness to agonist to be retained, fresh supplies of
receptor are required to be mobilized to the cell surface. Deliv-
ery to the membrane requires efficient transport between the
ER/Golgi/plasma membrane, which can be facilitated through
discrete motifs that reside within the synthesized protein (24,
25). Many chaperone proteins, such as coat protein complexes
(COPI and COPII), can assist transport of recently synthesized
proteins throughmotif-based sorting (26–28). Properly assem-
bled proteins are packaged for export intoCOPII vesicleswhere
they progress to the ER-Golgi intermediate complex, a process
known as anterograde transport. Misfolded proteins or those
exposing sequences encoding ER retentionmotifs (for example,
RXR, KDEL, or KKAA motifs) are shuttled back to the ER via
COPI vesicles, in a process known as retrograde transport (29).
During the assembly of multimeric proteins, such as GPCR
homo/heterodimers, proteins possessing ER retention signals
have been shown to evade ER retention through the steric
masking of motifs during protein folding (30–33). 14-3-3 pro-
teins have previously been shown to assist motif masking to
ensure export of proteins to the Golgi (25, 34). Once proper
protein folding has been achieved, post-translational modifica-
tions, such as complex glycosylation, will occur (35).
Here we identify for the first time the presence of an argin-
ine-based ER retention motif within intracellular loop-2 of
PAR4, which results in ER retention through COPI-dependent
retrograde transport. In the presence of PAR2, through PAR2/
PAR4 heterodimer formation and interaction with 14-3-3,
PAR4 was able to evade ER retention and undergo N-linked
complex glycosylation. This resulted in efficient delivery to the
plasmamembrane. The impact of enhanced cell surface expres-
sion was reflected in enhanced PAR4-mediated cell signal
transduction. PAR2 is often co-expressed with PAR4, and they
are dual up-regulated by various pro-inflammatory mediators
and have been shown to be co-activated by common agonists
(20, 36, 37). In the presence of PAR2, a significant increase in
PAR4-mediated total inositol phosphate accumulation was
observed. This work demonstrates for the first time a novel
regulatory role for PAR2 in the anterograde traffic and signaling
of PAR4. This is mediated by selective interaction with COPI or
14-3-3 proteins, offering a new paradigm for class A GPCR
trafficking and control.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies—The PAR4 activating peptide,
Ala-Tyr-Pro-Gly-Lys-Phe-amidated (NH2) peptide (AYPGKF-
NH2), was synthesized by theUniversity of Calgary Peptide Ser-
vice (Calgary, Canada). ER-TrackerTM Blue-White DPX Dyes
(Molecular Probes) for ER labeling and the anti-transferrin
receptor mouse monoclonal antibody were purchased from
Invitrogen Ltd. Rabbit polyclonal anti-Na,K-ATPase 1
antibody was purchased from Cell Signaling Technology Inc.
Living Colors full-length A.v. GFP rabbit polyclonal antibody
was purchased from Clontech-TaKaRa Bio Europe (France).
PKH26 Red Fluorescent Cell Linker kit for general cell mem-
brane labeling, anti-PAR4 goat polyclonal, anti-14-3-3 rabbit
polyclonal antibodies, monoclonal anti-HA-agarose conjugate,
HA peptide, and tunicamycin were from Sigma. The anti-PAR4
rabbit polyclonal antibody was obtained from Abcam (Cam-
bridge, UK). Anti- coatomer protein (-COP1) rabbit poly-
clonal antibody was purchased from Pierce and Thermo Fisher
Scientific (Loughborough, UK). Mouse monoclonal anti-HA
antibody was purchased from Cambridge Bioscience (Cambs,
UK). Pierce Cell Surface Protein Isolation Kit was purchased
fromThermo Scientific. The alkaline phosphatase substrate kit
was obtained from Bio-Rad.
Epitope-tagged PAR Constructs—Human PAR2 was ampli-
fied by polymerase chain reaction (PCR) from a pRSV-PAR2
vector.
The PCR product was then digested with HindIII-BamHI and
cloned into the respective sites of a pEYFP-N1 vector (Clontech).
Human PAR4 was amplified from a pcDNA3.1()-hPAR4 vector
byPCRanddigestedwithKpn-AgeI, whereas ECFPwas amplified
from the pECFP-N1 vector (Clontech) and digested with AgeI-
XbaI. PAR4 andECFPwere ligated and cloned into theKpnI-XbaI
sites of the pcDNA3.1() vector. Monomeric ECFP and EYFP
constructs were generated by amino acid substitution of Ala206 to
Lys206 (38), through site-directed mutagenesis using the Gene
TailorTM Site-directed Mutagenesis System (Invitrogen). Amino
acid substitutions were similarly made within the primary
sequence of PAR4 to mutate potential arginine-based ER reten-
tion motifs (positions R183AR 3 A183AA, (referred to as RAR
mut) R188GRR 3 A188GAA and R183AR R188GRR 3
A183AA A188GAA) and the N-linked glycosylation site on the
N-terminal of PAR4 (Asn563 Ala56). A HA epitope tag (YPYD-
VPDYA)was incorporated into theC-terminal of PAR4 byPCR to
generate PAR4-HA.All constructswere confirmedby sequencing.
Cell Culture—HEK293 cells were maintained in minimal
essential medium with Earle’s salts, L-glutamine supplemented
with 10% fetal calf serum (FCS), penicillin (100 units ml1),
streptomycin (100 g ml1), and nonessential amino acids and
passaged using 1 SSC (sodium citrate, pH 7.4). NCTC-2544
cells and NCTC-PAR2 cells were grown in Medium 199 with
Earle’s salts (Sigma) containing 10% FCS, sodium bicarbonate
(50 mM), L-glutamine (2 mM), penicillin (100 units ml1), and
streptomycin (100 g ml1). NCTC-2544 cells were passaged
using Versene (0.53 mM EDTA in PBS) to avoid trypsin expo-
sure. All cells where then incubated at 37 °C in a humidified
atmosphere with 5% CO2 with medium replaced every 2 days.
Transient Transfection—Cells were grown in 12- and 6-well
plates or T75 flasks prior to transient transfection at 70–80%
confluence with 1, 2, or 10 g of endo-free plasmid DNA,
respectively, using Lipofectamine 2000 (Invitrogen) following
the recommended manufacturer’s guidelines. Maximal gene
expression was observed 48 h post-transfection.
Inositol Phosphate Accumulation Assay—Following tran-
sient transfection for 24 h, cells were serum starved for a further
24 h in serum-free medium supplemented with 0.5 Ci/well (1
Ci  37 GBq) of myo-[2-3H]inositol (PerkinElmer Life Sci-
ences) (0.5Ci/well; 1 Ci 37GBq). Cells were pretreatedwith
20 mM lithium chloride for 30 min prior to agonist treatment
(100 M AYPGKF-NH2 for 45 min). Measurement of the accu-
mulation of inositol phosphates was carried out as previously
described by Plevin et al. (39).
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Fluorescence Microscopy—Cells were washed in PBS prior to
methanol fixation for 15 min at room temperature. After fur-
ther washes with PBS, cells were stained using 4,6-diamidino-
2-phenylindole (DAPI) nuclear dye or ER TrackerTM dye then
mounted onto glass microscope slides with 15 l of mowiol
(Calbiochem). Cells were visualized using a Nikon TE300-E
microscope (Nikon Instruments, New York) using a 100
(numerical aperture; NA 1.3) oil immersion Fluor lens. Emitted
fluorescence was detected using a photometric Cool Snap-HQ
monochrome camera (Roper Scientific, Trenton, NJ) set up in
12-bit mode (0–4095 gray tones). Metamorph software (ver-
sion 7.0, Molecular Devices Corp., Downing, PA) was used to
control image acquisition and modify image settings. Images
were background corrected, based on statistical correction of
average background regions from defined regions of interest.
Cell Surface ELISA—Changes in cell surface expression of
PAR4weremeasured byEnzyme-linked ImmunoSorbentAssay
(ELISA). Cells were transfected with PAR4 for 24 h prior to
being seeded at a density of 1  105 cells per well in 24-well
plates pre-coated with 0.1 ml/ml of poly-L-lysine. Cells were
grown overnight to recover. Surface receptors were pre-labeled
with anti-PAR4 (1/1000 dilution) at 4 °C for 1 h. Cells were fixed
in 3.7% paraformaldehyde for 5 min and then washed three
times in Tris-buffered saline (TBS; 20 mM Tris, pH 7.5, 150 mM
NaCl). Cells were blocked with 1% BSA in TBS for 45 min at
room temperature followed by a 1-h inculation with a alkaline
phosphatase-conjugated goat anti-rabbit antibody (1/1000
dilution) in 1% BSA in TBS. Cells were washed four times in
TBS to remove unbound secondary antibody. Alkaline phos-
phate substrate solution was prepared by dissolving p-nitro-
phenyl phosphate tablets in diethanolamine buffer (Bio-Rad).
Substrate solution was added to cells and the plates were incu-
bated at 37 °C for 10–30min. Absorbance wasmeasured at 405
nm using a microplate reader (Dynex MRX revelation).
Cell Surface Biotinylation—Surface expression of PAR4 in
NCTC-2544 andNCTC-PAR2 cells wasmeasured by a biotiny-
lation assay using Pierce Cell Surface Protein Isolation Kit
(Thermo Scientific). Briefly, four T75 cm2 flasks ofNCTC-2544
orNCTC-PAR2 cells were transfectedwith PAR4mECFP. Cells
were labeled with Sulfo-NHS-SS-Biotin for 30 min at 4 °C on a
rocking platform. The biotinylation reaction was stopped
through the addition of a quench solution followed by further
incubation at 4 °C for 15 min. Cells were scraped and the flasks
were rinsed in Tris-buffered saline (TBS) and centrifuged at
1,000  g for 3 min. Supernatant was discarded and the cell
pellets were washed 3 times in TBS followed by centrifugation
at 1,000 g for 3 min. Cells were lysed using the provided lysis
buffer containing complete protease inhibitor mixture (Roche
Diagnostics) and sonicated on ice at low power to disrupt using
five 1-s bursts, then incubated at 4 °C for 30 min on an orbital
rotator. The cell lysates were then centrifuged at 10,000 g for
2 min at 4 °C. Clarified supernatants were transferred to a new
tube and incubated with NeutrAvidin-agarose for 60 min at
room temperature with end-over-end mixing using a rotator.
Supernatant/agarose slurry was centrifuged for 1 min at
1,000 g and the supernatantwas discarded. The agarose pellet
was washed 3 times in the wash buffer provided with the addi-
tion of complete protease inhibitormixture. SDS-PAGE sample
buffer (62.5mMTris-HCl, pH 6.8, 1% SDS, 10% glycerol, 50mM
DTT) was added to the sample, which was then heated in a heat
block for 5 min at 95 °C. The tubes were then centrifuged for 2
min at 1,000  g. PAR4 expression was detected by Western
blotting using antibodies specific for either PAR4 or GFP. Equal
expression of total levels of PAR4 mECFP in transfected cells
was confirmed by resolving the corresponding whole cell
lysates prepared from the same cells used for the biotinylation
experiments.
Western Blotting—Proteins were separated by 8–10% SDS-
PAGE and transferred onto nitrocellulose membrane. The
membranes were blocked for nonspecific binding in 2% BSA
(w/v) diluted in NATT buffer (50 mM Tris-HCl, 150 mM NaCl,
0.2% (v/v) Tween 20) for 2 h. The blots were then incubated
overnight with 50 ng/ml of primary antibody diluted in 0.2%
BSA (w/v) in NATT buffer then washed with NATT buffer at
15-min intervals for a further 90min. The blots were then incu-
bated with HRP-conjugated secondary antibody (20 ng/ml) in
0.2% BSA (w/v) diluted in NATT buffer for 2 h. After a further
90-min wash, the membranes were treated with ECL reagent
and exposed to Kodak x-ray film.
Subcellular Fractionation of ER and Plasma Membrane
Compartments—Cells were grown to 70–80% confluence in
5T150 cm tissue culture flasks prior to transient transfection
with PAR4 mECFP. The cells were harvested and the cell pellet
resuspended in 3ml ofHES buffer (25mMHEPES, 1mMEDTA,
and 250 mM sucrose, pH 7.4) supplemented with protease
inhibitors (25 g/ml of leupeptin, 10 g/ml of aprotinin, and 1
g/ml of PMSF). The cell lysate was homogenized using a pre-
cooled cell homogenizer (Isobiotec Precision Engineering, Ger-
many, German PatentOffice number 202 09 547.9) fittedwith a
size 10-m clearance tungsten carbide ballbearing. The homo-
genate was centrifuged at 500  g for 2 min at 4 °C and the
supernatant was transferred to a fresh tube and resuspended in
Opti-prep (Invitrogen) density gradient medium to create a
45% (v/v) density sample solution. A density gradient (30–10%)
was prepared using Opti-prep medium mixed in HES buffer
followed by ultracentrifugation at 72,000  g for 4 h at 4 °C to
separate plasma membrane, endosomal, and ER fractions (40).
Equal volume fractions (300l) were collected and precipitated
in 37.5% TCA, incubated on ice for 15 min, and centrifuged at
14,000  g for 15 min at 4 °C. The cell pellets obtained were
resuspended in 2 Laemmli sample buffer supplemented with
1Murea and resolved byWestern blotting. Subcellular fraction-
ation of ER and plasma membrane compartments were deter-
mined using Na,K-ATPase, transferrin receptor, and cal-
nexin antibodies as markers for plasmamembrane, endosomal,
and ER fractions, respectively.
Intermolecular FRET—Wide-field intermolecular FRET
microscopy was performed at room temperature in living cells
(41–43) on a Nikon TE2000-E inverted microscope (Nikon
Instruments, Melville, NY). Cells were grown on 0 thickness on
coverslips and transiently transfected with the appropriate
monomeric donor mECFP or acceptor mEYFP-tagged con-
structs. Coverslips were placed into a microscope chamber
containing physiological HEPES-buffered saline solution (130
mMNaCl, 5 mM KCl, 1 mM CaCl2, 1 mMMgCl2, 20 mMHEPES,
10 mM D-glucose, pH 7.4). FRET imaging was performed using
PAR2 Regulation of PAR4 Trafficking
16658 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287•NUMBER 20•MAY 11, 2012
 at UNIV OF STRATHCLYDE on July 29, 2013http://www.jbc.org/Downloaded from 
a 40 (numerical aperture; NA 1.3) oil immersion Fluor lens.
Emitted fluorescence was detected using a photometric Cool
Snap-HQmonochrome camera (Roper Scientific, Trenton, NJ)
set up in 12-bit mode (0–4095 gray tones). MetaMorph soft-
ware (version 7.6.4 Molecular Devices Corp.) was used to con-
trol both the microscopy hardware and multiwavelength fluo-
rescence image acquisition required for intermolecular FRET
detection. Donor 430 nm or acceptor 500 nm excitation light
was generated using a computer controlled Optoscan mono-
chromator (Cairn Research, Faversham, Kent, UK) coupled to a
103/W2mercury (Hg) arc lamp source (Cairn Research). Opti-
mization of illumination excitation centerwavelength andband
pass settings was performed to prevent cross-excitation, mini-
mize donor and acceptor bleed-through into the FRETchannel,
and ensure no recorded pixels within the channel images were
saturated above a gray level intensity value of 4095. The risk of
motion occurring during the sequential FRET imaging process
was minimized by using a high-speed filter wheel (Prior Scien-
tific Instruments, Cambridge, UK). Metamorph imaging soft-
ware was used to quantify the FRET images using the specified
bleed-through FRET method. Corrected FRET (FRETc) was
calculated using a pixel-by-pixel methodology using the equa-
tion FRETc FRET (coefficient BmECFP) (coefficient
A mEYFP), where mECFP, mEYFP, and FRET values corre-
spond to background corrected images obtained through the
donor mECFP, mEYFP, and FRET channels. B and A corre-
spond to the values obtained for the mECFP (donor) and
mEYFP (acceptor) bleed-through coefficients, respectively, cal-
culated using cells transfected with either the mECFP or
mEYFP protein alone. Ratiometric FRET (RFRET) values were
calculated from the measurements taken from raw FRET fluo-
rescence and dividing this value by the total spectral bleed-
through of the acceptor and donor into the FRET channel, i.e.
raw FRET divided by (acceptor multiplied by (a))  (donor
multiplied by (b)). In the absence of energy transfer (i.e. no
FRET occurrence), the RFRET value measured is 1, values
greater than 1 represent the occurrence of FRET, thus indica-
tive of protein interaction.
Co-immunoprecipitation—To measure PAR4 interaction
with 14-3-3, cells transiently expressing PAR4-HA were
washed with PBS prior to solubilization in lysis buffer (20 mM
HEPES buffer, pH 7.7, containing 50 mM NaCl, 0.1 mM EDTA,
0.1 mM Na3VO4, 0.1 mM PMSF, 10 mg/ml of aprotinin, 10
mg/ml of leupeptin, and 1% (w/v) Triton X-100). After a 1-h
rotation at 4 °C, the cell lysates were clarified by centrifugation
at 13,000 g for 5min at 4 °C. Supernatants were transferred to
fresh Eppendorf tubes and 50 l was removed for inputs. The
remaining lysate was pre-cleared with 30 l of protein G/pro-
tein A-agarose (Calbiochem) and placed in an rotator for 1 h at
4 °C. Sampleswere centrifuged at 4 °C for 5min at 5,000 g and
the pre-cleared lysate was transferred to fresh Eppendorf tubes
containing 30 l of monoclonal anti-HA-agarose conjugate
(Sigma) and rotated overnight at 4 °C. Samples were centri-
fuged at 4 °C for 5 min at 5,000 g, then washed with 500 l of
lysis buffer three times and proteins were eluted by incubation
with 30 l of anti-HA peptide (Sigma; 200 g/ml) for 10 min at
room temperature. Eluted proteins were removed and added to
10 l of 5 SDS sample buffer and boiled at 95 °C for 10 min
prior to SDS-PAGE.
Statistical Analysis—Where experimental data are shown as
a blot, this represents one of at least 3 experiments and data
represent the mean  S.E. Statistical analysis was by one-way
analysis of variance withDunnett’s post-test (*, p 0.05; **, p
0.01).
RESULTS
Intracellular Retention of PAR4 in the Endoplasmic
Reticulum—Tomonitor the expression level and localization of
PAR4, the receptor was tagged at the C terminus with a mono-
meric variant form of enhanced cyan fluorescent protein
(mECFP) and transiently expressed in keratinocyte-derived
NCTC-2544 cells. These cells provided an idealmodel for these
investigations, due to the lack of endogenous PAR expression
(44). The localization of PAR4 was initially monitored using
fluorescence microscopy of NCTC-2544 cells transiently
expressing PAR4 mECFP (Fig. 1A). In comparison to cells
expressing either PAR1mEYFP or PAR2mEYFP, PAR4mECFP
was largely retained inside the cell with only weak membrane
localization observed. Further microscopy in cells treated with
an ER tracker dye (Fig. 1B) highlighted that PAR4 mECFP was
predominantly retained in the ER.
Presence of a Functional Arginine-based ER Retention Motif
within PAR4—Analysis of the protein sequence for PAR4 iden-
tified two potential arginine-based (RXR) ER retention motifs
located within the intracellular loop-2 of the receptor (supple-
mental Fig. S1). Alignment of the primary sequences for all PAR
family members found that these motifs were unique to PAR4.
The contribution of these motifs in controlling the cellular
localization of PAR4was assessed by removing the arginine res-
idues by alanine substitution (RXR 3 AXA). Of the possible
motifs investigated, only mutation of the R183AR to A183AA
resulted in a loss of ER retention and allowed PAR4 to translo-
cate to the plasma membrane (Fig. 2A). Receptor expression
levelswere determined byWestern blotting (Fig. 2B). Following
expression of PAR4 mECFP the appearance of a protein band,
resolving around 65 kDa, was observed. This correspondedwell
with the predictedmolecular mass of PAR4mECFP (38 kDa for
PAR4 combined with 27 kDa for themECFP). As Fig. 2B shows,
as the expression of the R183AR mutant increased, the appear-
ance of multiple protein forms was observed, a doublet resolv-
ing around 65 kDa and a slightly larger species resolving
between 70 and 80 kDa. Subcellular fractionation of cells
expressing either PAR4 mECFP or the R183ARmutant was car-
ried out to separate plasma membrane, endosomal, and ER
compartments followed byWestern blot (Fig. 2C). The 65-kDa
protein species observed in cells expressing PAR4 mECFP or
mutant receptor reached maximal levels in ER and endosomal
fractions (lanes 4–7), co-locating with calnexin and transferrin
markers, respectively. These experiments identified that the
higher molecular mass species observed in cells expressing the
R183ARmutant reflected receptors located in the plasmamem-
brane and endosome compartments (lanes 1–4) as shown
using Na,K-ATPase and transferrin receptor markers,
respectively.
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Coat protein I complex (COPI) can target proteins for reten-
tion through recognition and interaction with RXRmotifs (29).
COPI is comprised of multiple subunits including -, -, -,
-, -, -, and -COP. The ability of COPI to interact with PAR4
was demonstrated through co-immunoprecipitation with the
-COP subunit of the COPI complex as shown in Fig. 2D.
PAR2 Facilitates Anterograde Transport of PAR4 and Interac-
tion with 14-3-3—The presence of the R183AR ERmotif in the
protein sequence contributed greatly to the retention of PAR4
in the ER.Despite the presence of this ER retentionmotif, as the
earlier original characterization studies show, PAR4 has the
ability to reach the plasma membrane and respond to protease
activation (20). During the assembly of multimeric proteins it
has been shown that ER motifs, particularly arginine-based ER
retentionmotifs (25), may bemasked to allow proteins to evade
the quality control processes in the ER (31, 45). Interestingly
when co-expressed with PAR2 mEYFP, PAR4 mECFP was
found to be localized at the plasma membrane with minimal
intracellular compartmentalization, as shown by confocal
microscopy in Fig. 3A. This was explored further by cell surface
ELISA using an N-terminal PAR4-specific antibody to quantify
differences in surface receptor levels in NCTC-2544 cells and
NCTC-2544 cells stably expressing PAR2 (NCTC-PAR2), as
shown in Fig. 3B. When PAR4 mECFP was expressed in
NCTC-2544 cells a small increase in absorbance (A405 nm)
was detected (0.676 0.05, *, p 0.05, n 4) compared with
control untransfected cells (0.495  0.05, n  4). When
expressed in NCTC-PAR2 cells, PAR4 surface expression was
significantly increased, as demonstrated by the enhanced
A405 nm reading (1.016  0.03, N4, ***, p  0.001 compared
with PAR4 in NCTC-2544 cells). Enhanced translocation of
PAR4 mECFP to the plasma membrane was not replicated
when co-expressed with PAR1 mEYFP (supplemental Fig.
S2). PAR4 was still largely localized intracellularly, with
PAR1/PAR4 co-localization observed predominantly within
vesicles.
As shown in Fig. 4A, similar membrane translocation was
observed for PAR4mECFPwhen transfected intoNCTC-PAR2.
FIGURE 1. Retention of PAR4 in the ER.NCTC-2544 cells expressing pcDNA3.1 empty vector, PAR1 mEYFP, PAR2 mEYFP, or PAR4 mECFP (green) were treated with
PKH26 red fluorescent cell linker dye to stain the plasma membrane (PM, red). Cells were fixed and treated with either (A) 4,6-diamidino-2-phenylindole (DAPI) to
identify nuclei (blue) or (B) ER marker (ER-Tracker Blue-White DPX Dyes, Molecular Probes) to identify the ER (blue). Cells were visualized using a100 Plan Fluor
objective. Images were merged to highlight distinct plasma membrane, nucleus, or ER compartments. Scale bars  10 m. White arrows point to the plasma
membrane, whereas red arrows are indicative of the intracellular/ER compartmentalization of PAR4. Image set representative of three separate experiments.
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In addition, when PAR4 mECFP was resolved byWestern blot-
ting two clear protein forms were detected when expressed in
NCTC-PAR2 cells (Fig. 4B). These results were similar to the
observations made in previous experiments resolving the ER
retention motif mutant PAR4 protein. Subsequent subcellular
fractionation of NCTC-PAR2 cells expressing PAR4 mECFP
highlighted the distinct differences in the compartmentaliza-
tion of PAR4. As Fig. 4B shows, the more rapidly migrating
65-kDa species was confined to ER and endosomal compart-
ments (lanes 4–6), whereas the distribution of the less rapidly
migrating form strongly correlated with ER, endosomal, and
plasma membrane fractions (lanes 1–6). Enhanced surface
expression of PAR4 was subsequently quantified using cell sur-
face biotinylation, as shown in Fig. 4C. Following biotinylation
of surface proteins, expression of PAR4 was probed using both
anti-GFP and anti-PAR4 specific antibodies inNCTC-2544 and
FIGURE 2.Mutation of the arginine-based ER retentionmotif (R183AR) enhances the cell surface expression of PAR4.A, NCTC-2544 cells expressing PAR4
mECFP or PAR4 RAR mECFP mutant (green) were treated to stain for the plasma membrane (PM, red) and nucleus (blue) as previously described. Cells were
visualizedusing a100Plan Fluor objective. Scale bars 10m. Intracellular retentionof PAR4mECFP is highlighted (red arrows), whereas notablemembrane
localization of the PAR4 RAR mECFP is evident (white arrows). B, protein expression was assessed using Western blotting of whole cell lysates expressing
increasing amounts of PAR4 mECFP or PAR4 RAR mECFP constructs as indicated. C, changes in the surface expression of PAR4 were confirmed by subcellular
fractionation using differential ultracentrifugation on an iodixanol gradient in cells expressing PAR4 mECFP or PAR4 RAR mECFP. Fractions were precipitated
and resolved by SDS-PAGE followed byWestern blotting. PAR4 mECFP (predicted band size65 kDa) was detected using a polyclonal GFP antibody capable
of recognizing the ECFP at the C-terminal of PAR4. Na
,K-ATPase (100 kDa), transferrin receptor (190 kDa), and calnexin (90kDa) antibodies were used
for the detection of membrane, endosomal, and ER compartments, respectively. D, interaction between PAR4 and COPI complex proteins was confirmed by
co-immunoprecipitation. Lysates from NCTC-2544 cells expressing PAR4 mECFP were subjected to immunoprecipitation (IP) and then probed for -COP1
interaction. Images and blots are representative of three separate experiments.
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NCTC-PAR2 cells transfected with PAR4 mECFP. Although
detection of surface PAR4 was negligible in transfected NCTC-
2544 cells (0.725  0.30-fold increase over mock transfected
cells, n 4), a significant increase in surface PAR4was detected
in NCTC-PAR2-transfected cells (5.199  0.85-fold increase
over mock cells, n  4). In addition to enhanced cell surface
expression of PAR4 in the presence of PAR2, a notable increase
in the ability of PAR4 to interact with the  isoform of the ER
export chaperone 14-3-3 was detected in co-immunoprecipita-
tion experiments (Fig. 4D). When PAR4-HA was expressed in
the parental NCTC-2544 cells, the ability of 14-3-3 to interact
with PAR4 was negligible. However, when PAR4-HA was
expressed inNCTC-PAR2 cells, the ability of 14-3-3 to interact
with PAR4 was clearly shown. Differential interaction of PAR4
with 14-3-3 was also demonstrated using GST pulldown
assays employing GST-14-3-3 fusion proteins (supplemental
Fig. S3). PAR4 binding to GST-14-3-3 was enhanced when
expressed in NCTC-PAR2 cells. In addition, interaction between
PAR4 and -COP1 was no longer observed during co-expression
of PAR2 and PAR4 (Fig. 4E and supplemental Fig. S3).
The localization of PAR4 was further explored in HEK293
cells, which have an endogenous level of PAR2 (Fig. 5). When
expressed, PAR4 mECFP was observed both at the plasma
membrane and in intracellular compartments (Fig. 5A), which
when resolved byWestern blot (Fig. 5B) identified similar pro-
tein species as in NCTC-2544 cells, representative receptor
populations were expressed at the cell surface and in ER/endo-
somal compartments (Fig. 5C).
FIGURE3.PAR2enhances surfaceexpressionofPAR4whenco-expressed inNCTC-2544 cells.NCTC-2544 cells expressingPAR4mECFP (cyan), PAR2mEYFP
(yellow), or co-expressing both constructs were fixed for confocal microscopy. Scale bars  25 m. A, membrane (white arrows) receptor expression is
highlighted, whereas intracellular receptor pools are indicated using red arrows. Images shown are representative of at least five independent experiments. B,
enhancement of PAR4 surface expression in the presence of PAR2 was subsequently quantified using a surface ELISA approach with an N-terminal anti-PAR4
antibody to detect changes in surface levels of PAR4. Data are presented as the optical density at 405 nm obtained from NCTC-2544 cells only (Control),
NCTC-2544 or NCTC-PAR4 cells expressing PAR4mECFP performed in at least three independent experiments. ***, p 0.001 one-way analysis of variancewith
Dunnett’s post-test.
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The novel features of PAR2/PAR4 co-expression were inves-
tigated further to identify if enhancement of the PAR4 cell sur-
face expression was a result of interaction between PAR2 and
PAR4. For this purpose, wide field intermolecular FRET imag-
ing was carried out (41, 42) in HEK293 cells expressing either
PAR4mECFPor PAR2mEYFP alone or co-expressing these two
FIGURE 4. PAR2 facilitates interaction between PAR4 and 14-3-3 but disrupts interaction with -COP1. PAR4 mECFP was transiently transfected into
NCTCoverexpressing PAR2 (NCTC-PAR2) cells.A, cells were treated, as describedpreviously, to identify the plasmamembrane (red) and nuclei (blue).Cellswere
visualized using a 100 Plan Fluor objective. Images were merged to highlight distinct plasma membrane/nuclear compartments. Scale bars  10 m.
Enhanced surface expression of PAR4 in NCTC-PAR2 cells is indicated by white arrows. B, protein expression was assessed using Western blotting in cells
expressing increasing amounts of PAR4 mECFP with the protein bands were detected separated by subcellular fractionation in NCTC-PAR2 cells and resolved
by Western blotting, as previously shown. C, enhanced surface expression was then quantitatively assessed by cell surface biotinylation of NCTC-2544 and
NCTC-PAR2 cells expressing PAR4 mECFP. Interaction between (D) PAR4-HA and 14-3-3 or (E) PAR4-mECFP and the COP subunit of COPI was assessed by
co-immunoprecipitation (IP) in NCTC-2544 and NCTC-PAR2 cells. Images and blots are representative of at least four independent experiments.
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constructs. As shown in Fig. 6A, an intracellular FRET signal
was observed, presumably in the ER and/orGolgi complex,with
a weak signal observed at the plasma membrane. When quan-
tified, co-expression of PAR2 mEYFP and PAR4 mECFP
resulted in a significant increase in RFRET (1.883  0.003)
when compared with experimental conditions where colli-
sional FRET could occur, i.e. co-expression of mEYFP and
mECFP in cells yielded a RFRET value of 1.173 0.055. Inter-
action between PAR2 and PAR4 was also demonstrated by co-
immunoprecipitation in HEK293 cells as shown in Fig. 6B.
These data indicate that PAR2/PAR4 heterodimerization
occurs and is likely responsible for enhanced cell surface
expression of PAR4.
We then examined the role of PAR2 in regulating further
post-translationalmodification of PAR4 in the context of recep-
tor maturation and cell surface expression. N-Linked complex
glycosylation is an important post-translational modification
for efficient cell surface delivery of GPCRs (46). Analysis of the
protein sequence of PAR4 identified an Asn-Xxx-serine/threo-
nineN-glycosylationmotif located at position 56 (N56DS) in the
N terminus of the receptor (supplemental Fig. S1), suggesting
that PAR4 may undergo N-linked glycosylation. To assess this,
first, pharmacological inhibition of glycosylation was carried
out using the GlcNAc phosphotransferase inhibitor tunicamy-
cin, which prevents all N-linked glycosylation. Fig. 7A shows
that pretreatment of HEK293 cells with tunicamycin elimi-
nated the higher molecular mass form of PAR4, whereas the
lower 65-kDa protein was still retained, with a minor interme-
diate band indicated. This effect was replicated in the R183AR to
A183AA mutant, known to be preferentially expressed at the
membrane. Experiments were then conducted using an N-ter-
minal mutant of PAR4 (Asn563 Ala56) to determine the effect
of PAR2 upon protein species expression (Fig. 7B) and receptor
localization (Fig. 7C). In control NCTC cells the PAR4 N56A
mutant construct (Fig. 7B, top panel) was expressed as a single
65-kDa protein form that corresponded to wild type PAR4
mECFP.When expressed in NCTC-PAR2 cells (Fig. 7B,middle
panel) a loss in the higher molecular mass protein form was
observed in comparison to wild type PAR4 mECFP, however,
the 65-kDa species was expressed alongside the slightly higher
molecular mass form previously observed in the tunicamycin
inhibition experiments. Similar results were obtained following
expression in HEK293 cells (Fig. 7B, lower panel). Correspond-
ing fluorescence microscopy images are shown in Fig. 7C. Lack
of PAR4 cell surface expression was observed following expres-
sion of the PAR4 N56A mutant in NCTC-PAR2 cells.
Finally, the effect of enhanced cell surface expression of PAR4
in the presence of PAR2 was explored further in relationship to
FIGURE 5.Membrane localization of PAR4 mECFP in HEK293 cells. PAR4 mECFP was transiently transfected into HEK293 cells that endogenously express
PAR2. A, localization of PAR4 at the cells surface is shown by co-localizationwith a plasmamembranemarker (white arrows). Cells were visualized using a100
Plan Fluor objective. Scale bars 10m. B, the protein band pattern of PAR4 expressionwas further assessed byWestern blot of transfectedwhole cell lysates
followed by subcellular fractionation (C) as previously described. Images and blots are representative of three separate experiments.
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PAR4-mediated cell signal transduction. As shown in Fig. 8,
NCTC-2544 and NCTC-PAR2 cells transiently expressing
PAR4 mECFP produced an increase in basal inositol phosphate
generation (NCTC, 4.59 0.45; NCTC-PAR2, 8.28 0.65-fold
of basal) compared with mock transfected cells. When each of
these cell systems was treated with the PAR4-specific activating
peptide, AYPGKF-NH2, a further increase in the inositol phos-
phate response was observed. When PAR4 was expressed in
NCTC-PAR2 cells total inositol phosphate (InsP1–4) accumu-
lation (50M agonist; 22.47 0.45 and 100M agonist; 21.16
2.62-fold of basal) was substantially greater than observed fol-
lowing expression of PAR4 in NCTC-2544 cells (50M agonist;
7.80 0.46 and 100 M agonist; 9.47 2.45-fold of basal).
DISCUSSION
Receptor traffic from the ER to the plasma membrane
involves highly coordinated events that in many cases may
require numerous accessory proteins and motif-based sorting
processes (35). The work presented here explores the mecha-
nisms through which PAR4 localization may be regulated. We
demonstrate for the first time the fundamental structural prop-
erties and protein interactions that govern PAR4 trafficking to
the plasma membrane. Furthermore, we reveal the critical role
of PAR2 in aiding plasma membrane expression of PAR4.
Initially we used bioinformatic analysis, which indicated that
PAR4 possesses a potential arginine-based (RXR) ER retention
motif in intracellular loop 2, similar in sequence to those of the
KA2 kainate (47) and 5HT3B serotonin (45) receptors. As such,
we considered that thismotifmight be responsible for retention
of PAR4 in the ER as an immature protein as shown in Fig. 1.
Unlike the KA2R and 5HT3BR, however, wheremutation of the
motif did not affect ER retention, mutation of the R183AR
sequence of PAR4 resulted in enhanced cell surface expression
as assessed by both indirect immunofluorescence and subcel-
lular fractionation. These findings are similar to previous stud-
ies showing efficient surface delivery followingmutagenesis of a
RSRR retention motif located within the C-terminal of the
GABAB1 polypeptide (24, 48). Protein complexes such as COPI
can target other proteins for retention through recognition and
interaction with RXR ER retention sequences (29), as demon-
strated for retention of KA2 receptors (33) and, indeed, our
studies showed PAR4 interaction with the -COP subunit of
the COPI complex (Fig. 2D). Equally, ER retention of KA2R
has been shown to correlate with an interaction with sub-
units that comprise the COPI chaperone system (33). Mis-
folded proteins or those containing sorting motifs such an
ER retention motif are known to be shuttled back to the ER
via COPI-containing vesicles (29). Our data in Fig. 4 show
FIGURE 6. FRET imaging and co-immunoprecipitation reveals heterodimer formation between PAR2 and PAR4 in HEK293 cells. PAR4mECFP and PAR2
mEYFPwere co-expressed inHEK293 cells.Wide field FRET imagingwasperformed in live cells.A, imageswere acquired for CFP, YFP, uncorrected FRET (uFRET),
with the uFRET channel corrected for spectral bleed-through/contamination (cFRET). Scale bars 25 m. Corresponding ratiometric FRET values were then
quantified and graphed. Data are expressed as mean S.E. from three separate FRET experiments (n 72 single cell measurements), **, p 0.001 one-way
analysis of variance with Dunnett’s post-test. B, interaction between PAR4-HA and PAR2mEYFPwas further assessed by co-immunoprecipitation (IP). Blots are
representative of at least three independent experiments.
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that indeed PAR4 is retrieved via a COPI-mediated system,
as found for KA2R.
Having defined the subcellular retention of PAR4, we sought
to determinewhatmechanismsmight facilitate transport to the
membrane because PAR4 is able to signal in a number of cell
types (49–51) and must reach the cell surface to be cleaved by
the proteinase agonists. One potential candidate was PAR2
because this receptor is often co-expressed with PAR4 and has
been shown to be co-activated by common agonists (20, 36, 37).
However, a key issue in exploring this possibility was the fact
thatmost cell lines currently studied express endogenous PAR2
at some level. In this present study, characterization of PAR4
subcellular distribution utilized NCTC-2544 cells because
these express negligible PAR receptor levels and this allowed a
direct assessment of the cellular distribution and function of
PAR4 in the absence and presence of PAR2. Indeed, prior stable
expression of PAR2 in this cell line revealed enhanced PAR4
plasma membrane expression compared with control NCTC
cells. These results were recapitulated in HEK293 cells that are
known to express endogenous PAR2 and in other cells types we
examined including human umbilical vein endothelial cells and
PC3 cells (not shown), which are also known to express PAR2
endogenously. Significantly, we show that enhanced plasma
membrane delivery of PAR4 by PAR2 has functional sequelae,
including increasing PAR4-mediated inositol phosphate accu-
mulation stimulated by a selective PAR4 agonist. To our knowl-
edge this is the first study to reveal such an interaction.
Howmay the presence of PAR2 facilitate PAR4 trafficking to
the membrane? In the secretory pathway proper folding and
assembly of GPCRs is essential for their efficient export to the
cell membrane and function (52). Isoforms of 14-3-3 proteins
have been shown to recognize and mask RXR motifs to direct
ER/Golgi export of multimeric proteins (34, 53). Interestingly,
we found that in the presence of PAR2, PAR4 becomes associ-
atedwith 14-3-3 and at the same time loses its associationwith
-COP1. This competitive interaction is similar to that
FIGURE 7. The presence of PAR2 allowsN-linked glycosylation of PAR4, which promotesmembrane localization.HEK293 cells were transfected with (A)
PAR4mECFPorPAR4RARmutant constructs. PreventionofdenovoN-glycosylationwas carriedoutby theadditionof tunicamycin (2g/ml) to transfected cells
as indicated for 16 h. B,NCTC, NCTC-PAR2, and HEK293 cells were transfectedwith increasing concentrations of the PAR4 N
56AmECFPmutant or PAR4mECFP.
Whole cell lysates were prepared and resolved by Western blotting. C, fluorescent microscopy confirmed a loss of surface localization of PAR4 following
mutation ofN-glycosylation site (red arrows). Cells were visualized using a100 Plan Fluor objective. Scale bars 10m. Blots and images are representative
of three independent experiments.
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observed for an ATP-sensitive potassium (KATP) channel, in
which COPI competes with 14-3-3 and - isoforms for inter-
action with the RKR motif on the cytosolic domain of each 
subunit of the channel to facilitate ER retention (34). Because
we also demonstrate PAR2/PAR4 heterodimerization by FRET
and co-immunoprecipitation, this suggests that interaction
with PAR2 increases the affinity of PAR4 for 14-3-3 binding.
Thus, we have identified a critical early checkpoint in the secre-
tory pathway involved in the processing of PAR4 and PAR2/
PAR4 heterodimer assembly, involving COPI and 14-3-3
chaperone systems, which explains the effects described above.
Interestingly, when similar FRET experiments were conducted
in the NCTC-2544 cell model, where co-expression with PAR2
enhances surface expression with minimal intracellular com-
partmentalization, interaction at the membrane was negligi-
ble.3 Unlike the ability of class C GPCRs to form stable dimers,
the current findings may indicate interaction between PAR2
and PAR4 to be of a reversible and transient nature. This is akin
to a number of other recent examples of GPCR dimerization
that are transient and presumably defined by Mass-Action (54,
55). This would both allow PAR4 to evade intracellular reten-
tion and, once at the cell surface, to be free to function in a
monomeric or homodimeric state. This concept is currently
under investigation.
We provided further confirmation of a role of PAR2 in regu-
lating PAR4 trafficking in the context ofN-linked glycosylation.
This was initially detailed by pretreatment of wild type-PAR4
(or the RAR mutant receptor) with tunicamycin or expression
of PAR4 mutated at the N-linked motif, located at position
N56DS within the N-terminal domain. Both approaches abol-
ished the presence of the mature PAR4 form and prevented cell
surface expression. Similar effects have previously been shown
for the dopamine D5 receptor (46) where mutagenesis of spe-
cific Asn-linkedmotifs resulted in ER retention of the receptor.
Despite the presence of an N-linked glycosylation motif
(N56DS), PAR4 was unable to undergo complex glycosylation,
unless in the presence of PAR2. We also identified that N-gly-
cosylation was a critical process in PAR2-mediated delivery of
PAR4 to the cell surface. Mutagenesis of the N-linked motif
resulted in intracellular retention of PAR4, despite the presence
of PAR2.
To our knowledge, despite work detailing the involvement of
COPI/14-3-3 in the intracellular transport of class C GPCRs
and ion channels, our data are the first to describe such inter-
actions for a well established class A GPCR family such as the
PAR family. However, recent studies on the intracellular traf-
ficking of a class A orphanGPCR,GPR15, detailed a critical role
for the binding of 14-3-3 (to an RXR motif located at the
extreme C-tail of the receptor) in its surface localization (56).
Although studies have demonstrated PAR1/PAR4 (57) and
PAR1/PAR3 heterodimerization (58), this is the first study to
reveal a functional interaction between PAR2/PAR4. Het-
erodimer formation between PAR2 and PAR4 impacted signif-
icantly upon other protein interactions with COPI and 14-3-3,
and by affecting the subcellular localization of PAR4, substan-
tially enhanced PAR4-mediated signal transduction. PAR2 and
PAR4 have been previously shown to be dual up-regulated by
tumor necrosis factor , a potent proinflammatory mediator
(59, 60). An increase in PAR2 has been linked to the progression
of chronic inflammation (2, 61), with a role for PAR4 in acute
inflammation being implicated in other models of arthritis (62,
3 M. R. Cunningham, J. D. Pediani, G. Milligan, and R. Plevin, unpublished
observations.
FIGURE 8. Enhanced PAR4-mediated [
3H]inositol phosphate accumulation in the presence of PAR2.NCTC-2544 and NCTC-PAR2 cells transiently express-
ing PAR4 mECFP were serum starved with serum-free growth medium supplemented with 0.25 Ci ofmyo-[2-
3H]inositol for 24 h. Cells were pretreated with
10mM lithiumchloride for 15minprior to stimulationwithAYPGKF-NH2 as indicated for 45min. Total inositol phosphate (InsP1–4) accumulationwasmeasured
via anion exchange. The data are representative values performed in triplicate (mean S.E.) over three independent experiments (**, p0.01).
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63). Co-expression of these receptors in these pathophysiolog-
ical environments, where tumor necrosis factor  is abundant,
may be pivotal to the progression of a PAR2/PAR4-mediated
proinflammatory response. In this study we identified a novel
heterodimer partnership formed between PAR2/PAR4, which
allows PAR4 to bypass COPI-dependent retrograde transport
and exit the ER to undergo post-translational modification to
be delivered to the plasmamembrane as amature glycoprotein.
These findings may be important in the understanding of the
roles of each receptor in the context of inflammation.
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